NOWDiagnostics
Developer and manufacturer of over-the-counter (OTC) and point-of-care (POC) rapid diagnostic tests. The company designs self-contained lateral flow immunoassays optimized for small-volume capillary blood (fingerstick) and has commercialized OTC and professional-use products while pursuing molecular and instrumented platforms. Headquartered in Springdale, Arkansas, with manufacturing facilities in the U.S.
Industries
Nr. of Employees
small (1-50)
Patents
Diagnostic testing assays and related devices with security and methods of use thereof
US-11255845-B2
View DetailsSimple LAMP PCR design for low resource setting and minimal environmental footprint
US-11052330-B2
View Details
Diagnostic testing assays and related devices with security and methods of use thereof
US-11255845-B2
View DetailsSimple LAMP PCR design for low resource setting and minimal environmental footprint
US-11052330-B2
View DetailsProducts
Rapid in‑home syphilis antibody test (OTC)
A self-contained lateral flow immunoassay intended for over-the-counter, in-home qualitative detection of syphilis antibodies using a single drop of capillary blood with results in minutes.
Rapid fingerstick hCG pregnancy test for clinical use
A rapid immunoassay for qualitative detection of human chorionic gonadotropin (hCG) from whole blood (venous or fingerstick), plasma, or serum designed for bedside and clinical use without need for external analyzers.
Rapid in‑home syphilis antibody test (OTC)
A self-contained lateral flow immunoassay intended for over-the-counter, in-home qualitative detection of syphilis antibodies using a single drop of capillary blood with results in minutes.
Rapid fingerstick hCG pregnancy test for clinical use
A rapid immunoassay for qualitative detection of human chorionic gonadotropin (hCG) from whole blood (venous or fingerstick), plasma, or serum designed for bedside and clinical use without need for external analyzers.
Services
End-to-end development and production of self-contained rapid tests for consumer and clinical use, including design, validation, and manufacturing.
Commercial distribution and channel development services to place diagnostic tests into professional, hospital, retail, and direct-to-consumer channels.
End-to-end development and production of self-contained rapid tests for consumer and clinical use, including design, validation, and manufacturing.
Commercial distribution and channel development services to place diagnostic tests into professional, hospital, retail, and direct-to-consumer channels.
Expertise Areas
- Over-the-counter and point-of-care diagnostic development
- Lateral flow immunoassays
- Assay development and reagent production
- Clinical performance studies and validation
Key Technologies
- Lateral flow immunochromatographic assays
- Buffer-less lateral flow device design
- Capillary (fingerstick) blood sampling
- Plasma separation membrane technology
News & Updates
FDA granted De Novo marketing authorization for an OTC rapid syphilis antibody test that provides in-home results in 15 minutes; clinical study (n=1,270) reported NPA 99.5% and PPA 93.4% versus laboratory comparators.
Agreement naming a major laboratory as exclusive U.S. distributor for professional and hospital channels to broaden access to the rapid syphilis test; Labcorp to offer the test via professional and consumer channels.
Announcement of nationwide retail and online availability of the rapid in-home syphilis test across major retailers and online marketplaces.
Company presentation highlighting commercial milestones including FDA authorization, market launch, Series B funding, and distribution partnerships.
Announcement of new CEO with experience in diagnostics commercialization and regulatory pathways; mentions product portfolio and molecular platform pipeline.
Company raised $22.5M in a Series B round to support commercialization and scaling efforts (referenced in investor communications).
FDA granted De Novo marketing authorization for an OTC rapid syphilis antibody test that provides in-home results in 15 minutes; clinical study (n=1,270) reported NPA 99.5% and PPA 93.4% versus laboratory comparators.
Agreement naming a major laboratory as exclusive U.S. distributor for professional and hospital channels to broaden access to the rapid syphilis test; Labcorp to offer the test via professional and consumer channels.
Announcement of nationwide retail and online availability of the rapid in-home syphilis test across major retailers and online marketplaces.
Company presentation highlighting commercial milestones including FDA authorization, market launch, Series B funding, and distribution partnerships.
Announcement of new CEO with experience in diagnostics commercialization and regulatory pathways; mentions product portfolio and molecular platform pipeline.
Company raised $22.5M in a Series B round to support commercialization and scaling efforts (referenced in investor communications).